Skip to main content

Kyowa Hakko Kirin Using Activiomics' Phosphoproteomics Platform for Drug Discovery

NEW YORK (GenomeWeb News) – Activiomics announced recently a research deal with Kyowa Hakko Kirin for use of Activiomics' mass spectrometry-based technology to "elucidate signaling mechanism of lead compounds in relevant cell-based systems."

Under the deal, the Japanese pharmaceutical firm will use Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology to identify important biomarkers that can be used in the drug-discovery process.

Financial and other terms of the agreement were not disclosed.

TIQUAS uses mass spectrometry to detect and quantify phosphorylation sites from a cell or tissue extract, which can be used to discover which proteins and pathways are activated. Changes in phosphorylation status signal a change in protein activity.

The deal was signed as part of Activiomics' strategic partnership with BioFocus announced during the summer and is its first entry into the Japanese market, the company said. Based in London, Activiomics is a privately held spinout of the Barts Cancer Institute.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.